On June 9, 2021 Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, reported an update on research and development efforts on its proprietary technology platform, XR-17 (Press release, Oasmia, JUN 9, 2021, View Source [SID1234583764]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In addition to building a strong clinical product pipeline in cancer indications, Oasmia is committed to enhancing XR-17 which can be applied to medicines used in many therapeutic areas.
Recent progress in research aiming to enhance the XR-17 drug delivery platform has been made as follows:
XR-18 – Enhancement of the XR-17 platform: XR-18 is a research and development effort based on the XR-17 technology platform intended to provide enhanced properties that improve clinical formulations and applications of active pharmaceutical ingredients (APIs) for cancer treatment. This effort has recently generated promising data including:
Addition of components to existing XR-17 formulation improving certain properties.
Synthesis of novel excipients exhibiting XR-17-like properties with enhanced stability characteristics. These modifications will be evaluated for feasibility in various drug formulations.
XR-19 – Encapsulation of multiple APIs: XR-19 is an enhancement of existing XR-17 features with new functionalities, specifically the encapsulation of multiple APIs in one micellar envelope. Recent proof-of-concept studies have shown novel capabilities of the XR-17 platform, demonstrating its potential for dual encapsulation of APIs. Subsequent research demonstrated the molecular makeup of the encapsulation, providing the basis for future development. The Company will move forward and explore applications in cancer and other indications.
The company is pursuing intellectual property enhancements for these opportunities.
Dr. Reinhard Koenig, Oasmia’s Chief Scientific Officer added, "Oasmia has a growing pipeline of oncology programmes in clinical development. Internal research intended to expand applications of Oasmia’s XR-17 technology platform is ongoing and showing progress. Depending on our ongoing research, we hope to add more options to our future oncology portfolio. We look forward to progressing the research programme and to reporting progress in the future."